Glucagon like peptide-1

ApprovedPeptide

UUniversity Hospital, Gentofte, Copenhagen

Glucagon like peptide-1 is one of 161 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.

Indications

Total Trials

Active Trials

160

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusApproved

AngioedemaActive, not recruiting

HypoglycemiaActive, not recruiting

Heart FailureActive, not recruiting

Type 2 DiabetesActive, not recruiting

Type 1 DiabetesActive, not recruiting

Type 2 Diabetes MellitusApproved

Approved

AngioedemaPreclinical

Active, not recruiting

HypoglycemiaPreclinical

Active, not recruiting

Heart FailurePhase 1

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Glucagon like peptide-1

UUniversity Hospital, Gentofte, Copenhagen

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 5

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 8

Forxiga

AstraZeneca

Preclinical

3 9

Acipimox

Boehringer Ingelheim

Preclinical

2 10

GLP-1

RRigshospitalet, Denmark

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

GLP-12 trials

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

Terminated·—·Phase 1/2·NCT00609154·20 enrolled

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

Completed·HHvidovre University Hospital·N/A·NCT00612625·9 enrolled

Type 2 Diabetes Mellitus1 trial

Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT00923962·35 enrolled

Heart Failure1 trial

The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

Completed·PPapworth Hospital NHS Foundation Trust·Phase 1·NCT02129179·10 enrolled

Pancreatic1 trial

Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

Unknown status·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT02944110·20 enrolled

Type 2 Diabetes1 trial

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruiting·—·Phase 4·NCT06449235·938 enrolled

9 more indications

Critically Ill Patients1 trial

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

Terminated·JJohns Hopkins University·Phase 2·NCT00798590·19 enrolled

Hemodynamic1 trial

Acute Effects of GLP-1 on Renal Hemodynamics

Completed·RRigshospitalet, Denmark·N/A·NCT04337268·10 enrolled

Angioedema1 trial

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Completed·VVanderbilt University·N/A·NCT01413542·44 enrolled

Beta-cell Function1 trial

Beta-Cell Function After Near-Normalisation of Blood Glucose

Completed·HHvidovre University Hospital·N/A·NCT00612950·8 enrolled

Hypoglycemia1 trial

The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia

Completed·UUniversity of Aarhus·N/A·NCT00418288·10 enrolled

Type 1 Diabetes1 trial

Glucagon-like Peptide-1 in Type 1 Diabetes

Withdrawn·UUniversity of Maryland, Baltimore·Phase 1·NCT04355832

Diabetes1 trial

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT03081676·20 enrolled

Inflammation1 trial

The Differential Effects of Diabetes Therapy on Inflammation

Completed·UUniversity College Dublin··NCT02150707·17 enrolled

Heart1 trial

The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men

Completed·UUniversity of Aarhus·N/A·NCT00256256·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Glucagon like peptide-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucagon like peptide-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucagon like peptide-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Gentofte, Copenhagen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital, Gentofte, Copenhagen

Glucagon like peptide-1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

GLP-12 trials

Type 2 Diabetes Mellitus1 trial

Heart Failure1 trial

Pancreatic1 trial

Type 2 Diabetes1 trial

Critically Ill Patients1 trial

Hemodynamic1 trial

Angioedema1 trial

Beta-cell Function1 trial

Hypoglycemia1 trial

Type 1 Diabetes1 trial

Diabetes1 trial

Inflammation1 trial

Heart1 trial

References

Drug Info

Quick Facts

Related News